Off-label drug use in the treatment of polycystic ovary syndrome

被引:40
作者
Vitek, Wendy [1 ,2 ]
Alur, Snigdha [2 ]
Hoeger, Kathleen M. [1 ,2 ]
机构
[1] Univ Rochester, Med Ctr, Div Reprod Endocrinol, Rochester, NY 14642 USA
[2] Univ Rochester, Med Ctr, Dept Obstet & Gynecol, Rochester, NY 14642 USA
关键词
PCOS; drug therapy; hirsutism; insulin resistance; D-CHIRO-INOSITOL; DOUBLE-BLIND; INSULIN-RESISTANCE; OVERWEIGHT WOMEN; SYNDROME PCOS; METFORMIN; THERAPY; PLACEBO; FLUTAMIDE; COMBINATION;
D O I
10.1016/j.fertnstert.2015.01.019
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Polycystic ovary syndrome (PCOS) is a complex lifelong disorder with an etiology and pathophysiology that is not yet entirely understood. Women with PCOS have clinical presentations that may vary from adolescence to menopause, including menstrual irregularity/anovulation and symptoms of hyperandrogenism, such as acne and hirsutism. Over a lifetime, treatment needs and requirements can change. Unfortunately, there are no Food and Drug Administration-approved medications that are approved solely for the purpose of PCOS, but the symptoms and presentation of PCOS are often amenable to several approved agents, such as oral contraceptives for the indication of acne and clomiphene citrate for the indication of induction of ovulation. However, to meet the needs of women with PCOS, off-label use of medications has flourished. This review explores the data for those agents that do not carry an indication for PCOS but have been used for treating the signs and symptoms of PCOS. ((c) 2015 by American Society for Reproductive Medicine.)
引用
收藏
页码:605 / 611
页数:7
相关论文
共 49 条
[1]  
[Anonymous], 2009, Obstet Gynecol, V114, P936, DOI 10.1097/AOG.0b013e3181bd12cb
[2]  
[Anonymous], BMJ
[3]  
[Anonymous], CLIN EVID
[4]  
[Anonymous], 2011, INT J PEDIAT ENDOCRI
[5]   Fasting and post-prandial glucagon like peptide 1 and oral contraception in polycystic ovary syndrome [J].
Aydin, Kadriye ;
Arusoglu, Gulcan ;
Koksal, Gulden ;
Cinar, Nese ;
Aksoy, Duygu Yazgan ;
Yildiz, Bulent O. .
CLINICAL ENDOCRINOLOGY, 2014, 81 (04) :588-592
[6]   Treatment options for polycystic ovary syndrome [J].
Badawy, Ahmed ;
Elnashar, Abubaker .
INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2011, 3 :25-35
[7]   Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity [J].
Baillargeon, JP ;
Jakubowicz, DJ ;
Iuorno, MJ ;
Jakubowicz, S ;
Nestler, JE .
FERTILITY AND STERILITY, 2004, 82 (04) :893-902
[8]   Quality of life and psychological well being in polycystic ovary syndrome [J].
Barnard, L. ;
Ferriday, D. ;
Guenther, N. ;
Strauss, B. ;
Balen, A. H. ;
Dye, L. .
HUMAN REPRODUCTION, 2007, 22 (08) :2279-2286
[9]   Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance [J].
Celik, O. ;
Acbay, O. .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2012, 35 (10) :905-910
[10]   Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review [J].
Costello, Michael F. ;
Shrestha, Bhushan ;
Eden, John ;
Johnson, Neil P. ;
Sjoblom, Peter .
HUMAN REPRODUCTION, 2007, 22 (05) :1200-1209